Julio Rosenstock, MD

Julio Rosenstock, MD
 

Director, Dallas Diabetes and Endocrine Center
Clinical Professor of Medicine
University of Texas
Southwestern Medical Center
Dallas, Texas

What advantages are offered by the two fixed ratio combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide? Video

What advantages are offered by the two fixed ratio combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide?

From a practical, clinical perspective what advantages are offered by the two fixed ratio combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide that seem to be on their way to approval?
Julio Rosenstock, MD

Julio Rosenstock, MD

How do the PK/PD dimensions of GLP-1-RAs determine their proper alignment with specific glycemic regulation needs (FPG vs PPG) and with specific clinical profiles of patients with T2D? Video

How do the PK/PD dimensions of GLP-1-RAs determine their proper alignment with specific glycemic regulation needs (FPG vs PPG) and with specific clinical profiles of patients with T2D?

How do the PK/PD dimensions of GLP-1-RAs determine their proper alignment with specific glycemic regulation needs (FPG vs PPG) and with specific clinical profiles of patients with T2D?
Julio Rosenstock, MD

Julio Rosenstock, MD

What have your studies shown as far as the optimal way to advance basal insulin therapy, and combining basal insulin with either prandial insulin or a GLP-1 RA? Video

What have your studies shown as far as the optimal way to advance basal insulin therapy, and combining basal insulin with either prandial insulin or a GLP-1 RA?

What have your studies shown as far as the optimal way to advance basal insulin therapy, and combining basal insulin with either prandial insulin or a GLP-1 RA?
Julio Rosenstock, MD

Julio Rosenstock, MD